First and second generation Probiotic therapeutics for Inflammatory Bowel Disease

Publication date: Available online 22 June 2019Source: PharmaNutritionAuthor(s): Srijita Sireswar, Ishita Ghosh, Gargi DeyAbstractThe interaction between the intestinal biota and humans have co-evolved, directing both to a state of complementary tolerance. However, dysbiosis in intestinal microbiota leads to inflammatory bowel disease which results from an aggressive immune response towards specific components of the commensal, enteric bacteria in a genetically susceptible host. One of the popular strategies for prophylaxis and treatment of inflammatory bowel disease has been the use of immune-regulatory probiotic formulations. The purpose of this review was to assess the status quo of these probiotic formulations. Clinical trials performed through a span of 2002-2019 with probiotics, synbiotic and second generation probiotic formulations were analysed. The review tries to understand whether the probiotic formulations have proven to be clinically effective IBD therapeutics.Graphical abstract
Source: PharmaNutrition - Category: Nutrition Source Type: research